Growth Hormone Stack: CJC-1295 + Ipamorelin + Tesamorelin Protocol (2026)

The GH stack is shorthand for combining two mechanistic classes at the pituitary somatotroph to produce a growth hormone pulse larger than either class alone: a GHRH analog (CJC-1295 with or without DAC, or FDA-approved tesamorelin) plus a GHRP / ghrelin-receptor agonist (ipamorelin is the selective, low-side-effect option). The two classes act through separate receptors and separate second-messenger systems that converge on GH exocytosis; combined stimulation produces a pulse roughly 2 to 3 times larger than either agonist alone. This guide covers three protocol variants — Standard (community modal), Aggressive (body-composition focused), and Conservative (physician-guided) — with reconstitution math for all three components, IGF-1 monitoring cadence, side-effect management, and honest 2026 cost analysis. It is not a substitute for an endocrinologist; it is a reference for informed patients discussing options with their prescribing clinicians. For component-level pharmacology, see our individual guides on CJC-1295, Ipamorelin, and Tesamorelin, plus the head-to-head CJC-1295 vs Ipamorelin comparison.
Table of Contents
- What is the GH Stack?
- How the Stack Works
- 2026 Regulatory Status
- Standard Protocol (Community Modal)
- Aggressive / Body Composition Variant
- Conservative / Physician-Guided Variant
- Reconstitution Math
- Side Effects and Management
- IGF-1 Monitoring
- Cost Considerations
- Frequently Asked Questions
- References
What is the GH Stack?
The GH stack is a two-peptide (or three-peptide) protocol that combines a growth-hormone-releasing hormone (GHRH) analog with a growth-hormone-releasing peptide (GHRP) — also called a ghrelin-receptor agonist — to amplify endogenous GH secretion in a pulsatile pattern that resembles physiologic release. The stack works at the anterior pituitary, on the somatotroph cells that store and release GH, and its distinguishing feature is that it leverages the body’s own regulatory feedback (somatostatin and IGF-1) rather than bypassing it the way exogenous recombinant human GH (rhGH) does. That preserved feedback is the primary safety argument for stacking secretagogues over injecting rhGH directly.
Three peptides dominate the 2026 GH-stack conversation:
- CJC-1295 — a modified GHRH(1-29) analog that circulates in two versions. The DAC version (with a Drug Affinity Complex maleimidopropionyl linker) binds to serum albumin and has a plasma half-life of roughly 5.8 to 8.1 days, sustaining IGF-1 elevation for 9 to 11 days after a single injection (Teichman 2006, PMID 16352683). The no-DAC version (also called Mod GRF 1-29 or MOD-GRF-1-29) has no linker and a 30-minute half-life, closer to a physiologic pulse.
- Ipamorelin — a pentapeptide GHRP that selectively activates the ghrelin receptor (GHS-R1a) on somatotrophs and, unlike GHRP-6 and GHRP-2, does not raise ACTH, cortisol, or prolactin at physiologic doses (Raun 1998, PMID 9849822). This selectivity is why ipamorelin is the community-preferred GHRP for the stack.
- Tesamorelin — a synthetic GHRH(1-44) analog with a trans-3-hexenoyl protective group at Tyr1. This is the FDA-approved anchor of the stack (Egrifta / Egrifta SV / Egrifta WR, NDA 022505, approved November 10, 2010) for reduction of excess visceral abdominal fat in HIV-associated lipodystrophy. It has a large randomized Phase 3 dataset behind it (Falutz 2007 NEJM, PMID 18057338).
The stack most patients ask about is CJC-1295 (no-DAC) plus ipamorelin, injected together pre-bed to align with the natural nocturnal GH pulse. Practitioners with a body-composition focus and access to compounded FDA-approved product may substitute tesamorelin for CJC-1295, or layer ipamorelin on top of a tesamorelin baseline — a mechanism-based combination that has never been tested in a controlled trial.
How the Stack Works
Somatotroph cells in the anterior pituitary express two distinct receptors relevant to the stack, and each receptor funnels into a different second-messenger system that converges on GH exocytosis. This is why simultaneous stimulation is not merely additive.
GHRH-R (GHRH receptor). A 7-transmembrane G-protein-coupled receptor of the Gs class. Endogenous ligand: GHRH. Analog ligands: CJC-1295, tesamorelin, sermorelin. Binding activates adenylyl cyclase, raises intracellular cAMP, activates protein kinase A, opens voltage-gated calcium channels, and triggers GH exocytosis. Critically, GHRH also expands the releasable pool of GH stored in secretory vesicles — which is what makes GHRH synergistic with a GHRP that then triggers release from that expanded pool.
GHS-R1a (ghrelin receptor). A 7-transmembrane G-protein-coupled receptor of the Gq class. Endogenous ligand: ghrelin. Analog ligands: ipamorelin, GHRP-2, GHRP-6, hexarelin, and oral MK-677. Binding activates phospholipase C, generates IP3, releases intracellular calcium, and triggers GH exocytosis through a mechanistically separate pathway. GHS-R1a activation also acts at the hypothalamus to enhance GHRH release and suppress somatostatin.
Because the two pathways converge on GH exocytosis but arrive there through different second messengers, dual stimulation produces a GH pulse roughly 2 to 3 times larger than either agonist alone at the same dose. This is the mechanistic case for stacking a GHRH analog with a GHRP.
The CJC-1295 baseline. When used in no-DAC form (Mod GRF 1-29), CJC-1295 provides a 30-minute GHRH-receptor activation window that primes the somatotroph — expands the releasable GH pool and sensitizes the ghrelin-receptor response. When used in DAC form, CJC-1295 provides multi-day GHRH-receptor tone (5.8 to 8.1-day half-life per Teichman 2006), sustaining IGF-1 above baseline for 9 to 11 days after a single dose. The DAC version raises the “background” GHRH signal against which each ipamorelin pulse fires.
The ipamorelin pulse. Ipamorelin provides the acute GH-releasing pulse that draws from the CJC-primed releasable pool. Its selectivity — no cortisol, no ACTH, no prolactin — is what makes it stackable long-term without the endocrine collateral damage that comes with GHRP-6 or hexarelin.
The tesamorelin backbone. When tesamorelin substitutes for CJC-1295, the mechanism is pharmacologically the same (GHRH-receptor agonism), but the evidence base is deeper — Phase 3 RCT (n=412) in HIV lipodystrophy demonstrated 15.2% reduction in visceral adipose tissue at 26 weeks versus 5% increase with placebo. Some clinicians add low-dose ipamorelin to a tesamorelin baseline for the mechanistic synergy at the pulse peak. There is no controlled trial of tesamorelin plus ipamorelin; the combination is mechanism-based extrapolation, not evidence-based combination.
2026 Regulatory Status
Tesamorelin. FDA-approved. Original Egrifta (NDA 022505) approved November 10, 2010 for reduction of excess abdominal fat in HIV-associated lipodystrophy. Egrifta SV (Single-Vial reformulation, simplified reconstitution) approved 2019. Egrifta WR (F8 formulation, weekly reconstitution to reduce patient burden) is the currently-marketed formulation as of 2026 per Theratechnologies communications. The approved indication is HIV lipodystrophy only; off-label GH-optimization use in non-HIV populations is common in longevity and body-composition clinics but is not the FDA-labeled use and does not enjoy insurance coverage outside the HIV indication.
CJC-1295. Research peptide. Removed from the FDA Category 2 restricted list in September 2024. Included in the February 27, 2026 HHS reclassification announcement that moved a batch of previously-restricted peptides toward Category 1 status. CJC-1295’s final positioning is the most contested item in that batch — the Pharmacy Compounding Advisory Committee did not initially recommend it for the 503A bulks list, and the cardiovascular safety framing from the 2006 ConjuChem Phase 2 trial (one participant death, attributed by the attending physician to pre-existing coronary artery disease rather than treatment) remains in the discussion. Treat regulatory status as “in flux — verify at time of publish or dispensing.” Not FDA-approved as a drug in any formulation.
Ipamorelin. Research peptide. Removed from Category 2 in September 2024. Included in the February 27, 2026 HHS Category 1 reclassification announcement, positioned more favorably than CJC-1295 because ipamorelin has the cleaner safety signal (no cortisol/ACTH/prolactin spike; the Beck 2014 Phase 2 ileus trial with n=117 established a favorable acute safety profile even though the efficacy endpoint for postoperative ileus was null). Not on the July 23-24, 2026 PCAC review agenda. Not FDA-approved for any indication.
Combining them. No FDA guidance addresses the CJC-1295 plus ipamorelin combination directly because neither is FDA-approved. The tesamorelin prescribing information does not enumerate ipamorelin or CJC-1295 among known drug interactions. Clinicians who prescribe compounded stacks typically document the rationale in the medical record and monitor IGF-1 and fasting glucose per the schedule in the IGF-1 Monitoring section below.
Standard Protocol (Community Modal)
This is the most-reported community protocol for GH-secretagogue stacking as of mid-2026: CJC-1295 (no-DAC) plus ipamorelin, blended in a single syringe and injected subcutaneously 15 to 30 minutes before bed on an empty stomach. The pre-bed timing rationale is that endogenous GH pulses primarily during the first 90 minutes of slow-wave sleep, and aligning the pharmacologic pulse with the natural pulse avoids the insulin-suppressive effect of a recent carb load blunting GH release.
| Component | Weeks 1-8 (on-cycle) | Weeks 9-12 (off-cycle) | Weeks 13-20 (on-cycle) | Notes |
|---|---|---|---|---|
| CJC-1295 (no-DAC / Mod GRF 1-29) | 100-300 mcg SC pre-bed | None | 100-300 mcg SC pre-bed | Blend with ipamorelin in same syringe |
| Ipamorelin | 100-300 mcg SC pre-bed | None | 100-300 mcg SC pre-bed | Selective GHS-R1a agonist; no cortisol spike |
| Route | Subcutaneous, abdomen or thigh | N/A | Same | U-100 insulin syringe |
| Timing | 15-30 min pre-bed, empty stomach (last meal 2+ hrs prior) | N/A | Same | Aligns with natural GH pulse in first 90 min of slow-wave sleep |
Notes on the standard protocol. The 100 to 300 mcg dose range for each component is the community-modal range; most protocols start at 100 mcg each and titrate up over 2 to 4 weeks based on tolerance and subjective response. The “8 weeks on / 4 weeks off” cycling pattern is a cautious approach that limits continuous receptor exposure and gives the somatotroph a chance to reset — no controlled trial defines optimal cycle length, and shorter cycles (5 days on / 2 days off within a week) are also common. See our Injection Sites and Rotation Guide for site selection and rotation.
Optional morning dose. Some protocols add a second same-dose injection in the morning on training days. There is no controlled evidence that a morning dose improves body-composition or IGF-1 outcomes over a single pre-bed dose, and adding a morning injection increases the total daily GH exposure — which is worth watching if the goal is physiologic pulsatility rather than continuous elevation.
Adjunct interventions. The standard protocol assumes: adequate protein intake at 1.6 to 2.2 g/kg lean body mass, resistance training 3 to 4 sessions per week, 7 or more hours of sleep (GH pulses depend on slow-wave sleep architecture), and moderate rather than extreme caloric deficit. The stack is a support layer on top of those interventions, not a substitute for them.
Aggressive / Body Composition Variant
This variant is used by patients with a specific body-composition goal — visceral fat reduction, aesthetic recomposition, athletic recovery — who have discussed the elevated IGF-1 exposure with a physician and accepted the higher monitoring burden. Not recommended without medical supervision, and not appropriate for anyone with a personal history of cancer, uncontrolled diabetes, or unresolved edema. Duration: 12 to 24 weeks continuous, with quarterly IGF-1 checks.
| Component | Weeks 1-4 | Weeks 5-12 | Weeks 13-24 | Notes |
|---|---|---|---|---|
| CJC-1295 DAC | 1 mg SC Monday + Thursday | 1-2 mg SC Monday + Thursday | Hold at tolerated dose | 5.8-8.1 day half-life sustains GHRH tone |
| Ipamorelin | 200 mcg SC pre-bed nightly | 200-300 mcg SC pre-bed nightly | Same | Provides acute pulses on the DAC-sustained baseline |
| Route | Both SC, separate injections | Same | Same | DAC injected AM; ipamorelin at bedtime |
Why this is aggressive. CJC-1295 DAC produces sustained IGF-1 elevation for 9 to 11 days after each injection (Teichman 2006), meaning twice-weekly dosing maintains near-continuous GHRH tone. Adding nightly ipamorelin on top of that produces sustained IGF-1 elevation with periodic acute pulses — a different pharmacologic profile than the physiologic pulsatile pattern of the standard protocol. The higher total GH exposure is what drives visceral fat reduction and body-composition changes, and the same exposure raises insulin resistance, glucose intolerance, and edema risk.
Alternative aggressive protocol — Tesamorelin monotherapy at FDA-labeled dose. For patients with body composition as the goal, tesamorelin 2 mg SC daily pre-bed is the highest-evidence-grade option (Falutz 2007 Phase 3 RCT, 15.2% VAT reduction at 26 weeks). Effects on visceral fat become measurable by roughly 12 weeks and peak at 26 weeks. Some clinicians layer 100 to 200 mcg ipamorelin SC pre-bed on top of the 2 mg tesamorelin baseline for mechanistic synergy at the pulse peak — this combination has never been tested in a controlled trial and should be framed as mechanism-based extrapolation.
Physician monitoring recommendations. Baseline IGF-1, fasting glucose, HbA1c, comprehensive metabolic panel, and fasting insulin. Recheck IGF-1 and fasting glucose at 6 to 8 weeks, then every 12 weeks on-cycle. See Peptide Lab Testing Guide for the operational details of ordering these labs.
Conservative / Physician-Guided Variant
This variant is designed for patients who are working closely with a physician, have a personal or family history of cancer requiring IGF-1 monitoring, have baseline glucose intolerance, or want to prioritize safety and reversibility over body-composition velocity. It is also the appropriate starting point for anyone new to peptide therapy. Duration: 8 to 16 weeks, with a scheduled reassessment at midpoint.
| Component | Weeks 1-4 | Weeks 5-8 | Weeks 9-16 | Notes |
|---|---|---|---|---|
| CJC-1295 (no-DAC only) | 100 mcg SC pre-bed, 5 nights/week | 100-200 mcg SC pre-bed, 5 nights/week | Reassess at week 8; continue or discontinue | Short-acting, physiologic pulse pattern |
| Ipamorelin | 100 mcg SC pre-bed, 5 nights/week | 100-200 mcg SC pre-bed, 5 nights/week | Same | Blend with CJC in same syringe |
| Route | SC, abdomen or thigh | Same | Same | U-100 insulin syringe |
Rationale. The conservative variant uses only the short-acting no-DAC version of CJC-1295, avoiding the multi-day IGF-1 elevation that comes with the DAC version. Dosing 5 nights per week (Monday through Friday, weekends off) further limits continuous exposure and gives the axis regular recovery windows. Doses stay at the low end of the community range. The goal is to establish tolerance, verify IGF-1 rises predictably into the upper quartile of the age/sex reference range without exceeding it, and reassess at 8 weeks.
Best for whom. Patients with a personal or family history of cancer (any pathway that raises IGF-1 systemically warrants oncology sign-off first). Patients over age 65 who metabolize peptides differently and may develop edema more readily. Patients whose physicians prefer conservative dosing philosophies. First-time users establishing baseline tolerance before considering a longer-term protocol.
What “clinically guided” actually means. A physician-guided variant is not defined by the dose alone — it is defined by the presence of scheduled lab draws, a physician reviewing results, and a documented plan for what to do at each reassessment window. If your prescribing physician is willing to write the prescription but not follow the IGF-1 trajectory, this variant becomes indistinguishable from the standard protocol. The monitoring is what makes it conservative.
Reconstitution Math
CJC-1295, ipamorelin, and tesamorelin all arrive from compounding pharmacies or research-peptide vendors as lyophilized powders that must be reconstituted with bacteriostatic water for injection (BAC water, 0.9% benzyl alcohol preservative). Branded Egrifta / Egrifta SV / Egrifta WR arrives with its own diluent and reconstitution instructions specified in the prescribing information — follow the manufacturer instructions for branded product; the tables below cover compounded and research-peptide vials.
CJC-1295 no-DAC (Mod GRF 1-29) reconstitution (typical 2 mg or 5 mg vial):
| Vial size | BAC water | Concentration | Draw for 100 mcg dose | Draw for 200 mcg dose | Draw for 300 mcg dose |
|---|---|---|---|---|---|
| 2 mg powder | 2 mL | 1000 mcg/mL | 0.1 mL = 10 units U-100 | 0.2 mL = 20 units | 0.3 mL = 30 units |
| 5 mg powder | 2.5 mL | 2000 mcg/mL | 0.05 mL = 5 units | 0.1 mL = 10 units | 0.15 mL = 15 units |
| 5 mg powder | 5 mL | 1000 mcg/mL | 0.1 mL = 10 units | 0.2 mL = 20 units | 0.3 mL = 30 units |
CJC-1295 DAC reconstitution (typical 2 mg or 5 mg vial):
| Vial size | BAC water | Concentration | Draw for 1 mg dose | Draw for 2 mg dose |
|---|---|---|---|---|
| 2 mg powder | 2 mL | 1 mg/mL | 1 mL = 100 units U-100 | 2 mL = 200 units (whole vial) |
| 5 mg powder | 2.5 mL | 2 mg/mL | 0.5 mL = 50 units | 1 mL = 100 units |
Ipamorelin reconstitution (typical 5 mg or 10 mg vial):
| Vial size | BAC water | Concentration | Draw for 100 mcg dose | Draw for 200 mcg dose | Draw for 300 mcg dose |
|---|---|---|---|---|---|
| 5 mg powder | 2.5 mL | 2000 mcg/mL | 0.05 mL = 5 units U-100 | 0.1 mL = 10 units | 0.15 mL = 15 units |
| 5 mg powder | 5 mL | 1000 mcg/mL | 0.1 mL = 10 units | 0.2 mL = 20 units | 0.3 mL = 30 units |
| 10 mg powder | 5 mL | 2000 mcg/mL | 0.05 mL = 5 units | 0.1 mL = 10 units | 0.15 mL = 15 units |
Blended CJC + ipamorelin vial (10 mg total, 5 mg each):
| Vial size | BAC water | Concentration each | Draw for 100 mcg each dose | Draw for 200 mcg each dose |
|---|---|---|---|---|
| 5 mg CJC + 5 mg Ipa | 5 mL | 1000 mcg/mL each | 0.1 mL = 10 units U-100 | 0.2 mL = 20 units |
| 5 mg CJC + 5 mg Ipa | 2.5 mL | 2000 mcg/mL each | 0.05 mL = 5 units | 0.1 mL = 10 units |
Tesamorelin reconstitution (compounded 5 mg or 10 mg vial):
| Vial size | BAC water | Concentration | Draw for 1 mg dose | Draw for 2 mg dose |
|---|---|---|---|---|
| 5 mg powder | 2 mL | 2.5 mg/mL | 0.4 mL = 40 units U-100 | 0.8 mL = 80 units |
| 5 mg powder | 2.5 mL | 2 mg/mL | 0.5 mL = 50 units | 1 mL = 100 units |
| 10 mg powder | 2 mL | 5 mg/mL | 0.2 mL = 20 units | 0.4 mL = 40 units |
U-100 insulin syringes are the standard. A U-100 syringe reads in “units” where 100 units = 1 mL. Every dose in the tables above is expressed in both mL and U-100 units for easy translation. If your syringe is U-50 or U-40 (rare), the unit math changes — verify concentration and syringe scale before drawing. See our Reconstitution Beginner Guide for step-by-step instructions.
For automated math with any vial size and concentration, use the Peptide Toolkit Calculator. Select CJC-1295, ipamorelin, or tesamorelin from the dropdown, enter your vial size and BAC water volume, and it will output the exact draw for your target dose.
Side Effects and Management
Edema and joint pain. The most common, most reversible, and most predictable side effects of any GH-secretagogue protocol. Mechanism: GH raises aldosterone, which drives renal sodium retention and soft-tissue fluid accumulation, producing mild peripheral edema, periarticular pressure (arthralgia), and occasionally carpal-tunnel-like paresthesia from fluid compressing peripheral nerves in tight anatomic spaces. Management: dose-reduce, salt-restrict, and give the axis 3 to 5 days — symptoms typically clear within a week. If edema is severe, hold the peptide and consult your physician.
Insulin resistance and glucose dysregulation. The medium-term concern. IGF-1 above the physiologic range for months at a time raises fasting glucose and can push borderline patients toward insulin resistance or type 2 diabetes. Management: quarterly HbA1c and fasting insulin during any protocol running longer than 6 months. Cycle off if fasting glucose trends upward or HbA1c crosses into the pre-diabetic range.
Injection-site reactions. Erythema, pruritus, and small hematomas are common with any subcutaneous peptide. Rotate sites (abdomen, thigh, flank) with each injection. If reactions are severe or persistent, switch bacteriostatic water lots — some patients react to the benzyl alcohol preservative.
Tesamorelin-specific. Arthralgia and myalgia are the most-reported effects from the Phase 3 trial. Peripheral edema at similar rates to placebo in the trial but more pronounced in the off-label longevity population. Rare hypersensitivity reactions. The FDA label includes a warning to consider dose reduction or discontinuation if IGF-1 rises above the age and sex-adjusted normal range — 2 to 3 times the upper limit sustained is the practical cutoff most clinicians use.
Ipamorelin-specific. Mild transient hunger (ghrelin-receptor pharmacology, though much less than GHRP-6 or GHRP-2). Occasional headache. No hypercortisolism signal in trials; no prolactin elevation signal. Long-term safety beyond 6 months has not been characterized in controlled trials.
CJC-1295 DAC-specific. Because DAC keeps GH elevated for days, any side effect that appears will persist longer than with short-acting alternatives. The 2006 ConjuChem Phase 2 trial in HIV lipodystrophy was halted after one participant death — the attending physician attributed it to pre-existing coronary artery disease and plaque rupture rather than the peptide, and development was ultimately discontinued for commercial reasons. That trial history is why CJC-1295 DAC deserves an explicit “not first-line, use only if you understand the trial history” framing.
Malignancy concern. Any pathway that raises IGF-1 systemically is under active-cancer scrutiny. The FDA labels for GH-related therapies universally carry a warning about active malignancy. Anyone with active cancer, a recent cancer diagnosis, or a personal history of hormonally-driven cancer should not use GH secretagogues without oncology sign-off. The IGF-1/PI3K/AKT pathway is implicated in growth of several tumor types, and while a causal link between exogenous GH-secretagogue use and tumor progression has not been established in a controlled human trial, the mechanistic caution is appropriate.
For a complete drug interaction survey and adjacent-peptide compatibility, see our Peptide Interactions Tool.
IGF-1 Monitoring
Serum IGF-1 and body composition (waist circumference or DEXA) are the two most reliable objective markers of a working GH-stack protocol. GH itself is pulsatile and a random draw is nearly useless; IGF-1 integrates over roughly 24 hours and is the standard proxy for cumulative GH exposure.
Recommended cadence — adapted from adult-GH-replacement clinical practice, which is the closest analog for research-peptide protocols (there is no formal published guideline for GH-secretagogue monitoring in the off-label longevity population):
- Baseline (within 2 weeks before starting). Draw fasting IGF-1, fasting glucose, HbA1c, comprehensive metabolic panel (kidney and liver function), and lipid panel. Optional: DEXA scan for baseline body composition if the protocol goal is body-composition tracking.
- 6 to 8 weeks post-start. Repeat fasting IGF-1 to confirm the expected 1.5 to 3-fold rise into the upper quartile of the age/sex reference range. If IGF-1 sits above the age/sex-adjusted normal range persistently (greater than 2 to 3x ULN sustained), reduce dose or cycle off. Also repeat fasting glucose to screen for insulin-resistance signal early.
- Quarterly on-cycle. Fasting IGF-1 plus fasting glucose. Any user staying “on” continuously for more than 6 months should add HbA1c and fasting insulin to this quarterly panel.
- Off-cycle at 4 weeks. Confirm IGF-1 returns to within 20% of baseline after a 4-week off-cycle window. Persistent elevation after cessation warrants further workup — possible pituitary adenoma, other secretagogue interference, or occult acromegalic pathology.
See Peptide Lab Testing Guide for the operational details of ordering these labs through direct-access lab services and understanding the reference ranges.
Cost Considerations
Tesamorelin monthly cost, 2026 US pricing:
| Source | Product | Monthly cost | Notes |
|---|---|---|---|
| Branded pharmacy | Egrifta / Egrifta SV / Egrifta WR | $2,600 – $5,500 | Insurance coverage available for HIV-lipodystrophy indication with prior authorization; off-label use rarely covered |
| Compounded 503A/503B | Compounded tesamorelin vials | $200 – $450 | Availability varies by compounding pharmacy; verify with specific pharmacy before ordering |
| Research peptide vendor | 5 mg or 10 mg vial “research use only” | $70 – $130 | Not intended for human use; quality highly variable; regulatory gray area |
CJC-1295 monthly cost:
| Source | Product | Monthly cost | Notes |
|---|---|---|---|
| Compounding pharmacy | CJC-1295 (with or without DAC) with prescription | $150 – $350 | Typically 1-2 vials/month at community-modal dose |
| Research peptide vendor | 5 mg vial (either version) | $40 – $90 | DAC protocols consume more per month; no-DAC / Mod GRF 1-29 vials often cheaper |
Ipamorelin monthly cost:
| Source | Product | Monthly cost | Notes |
|---|---|---|---|
| Compounding pharmacy | 5 mg vial with prescription | $80 – $180 | Often blended with CJC-1295 in a 10 mg combo vial |
| Research peptide vendor | 5 mg vial “research use only” | $25 – $70 | Blended CJC + ipa 10 mg vials commonly $60 – $130 |
Total stack cost. Standard protocol (CJC-1295 no-DAC + ipamorelin via compounding pharmacy) runs approximately $230 to $530 per month. Aggressive protocol with tesamorelin baseline runs $280 to $630 per month via compounded 503A tesamorelin, or over $2,700 per month if using branded Egrifta. The branded pathway is only realistic for patients with an HIV-lipodystrophy diagnosis and insurance authorization.
Related purchases. Bacteriostatic water for reconstitution runs $10-15 per 30 mL vial (see where-to-buy bacteriostatic water). Insulin syringes at $15-25 per 100-count box (see where-to-buy insulin syringes). Alcohol swabs and sharps container are trivial cost. Lab draws for IGF-1 monitoring run $40 to $120 per panel through direct-access lab services; budget for quarterly panels.
Not to buy. Per our editorial policy, we do not link to research peptide vendors for CJC-1295, ipamorelin, tesamorelin, or any other research peptide. Compounding pharmacy sourcing via prescription is the recommended path for any peptide administered to humans. Research peptide vendors operate outside FDA oversight, quality varies dramatically, and endotoxin contamination is a documented concern in some products.
Frequently Asked Questions
Why stack a GHRH analog with a GHRP instead of using just one?
Somatotroph cells have two independently-signaled receptors that both trigger GH release — GHRH-R (via cAMP/PKA) and GHS-R1a (via PLC/IP3). Dual stimulation produces a GH pulse roughly 2 to 3 times larger than either agonist alone, because the GHRH class expands the releasable pool while the GHRP class triggers release from that expanded pool. Using one component alone still works, but the pulse is smaller and the pharmacologic case for “GHRH + GHRP synergy” rests on this mechanism.
Why is ipamorelin preferred over other GHRPs like GHRP-6 or GHRP-2?
Older GHRPs raise cortisol, ACTH, and prolactin alongside GH release, which is undesirable in a chronic-use protocol. Ipamorelin was specifically engineered for selectivity: the Raun 1998 paper (PMID 9849822) demonstrated in vitro and in animal models that ipamorelin releases GH with potency comparable to GHRP-6 and hexarelin but does not raise ACTH or cortisol even at doses over 200 times the effective GH-releasing dose. That selectivity is why it is the stack-preferred GHRP.
Should I use CJC-1295 with DAC or without?
No-DAC (Mod GRF 1-29) is the more common community starting point because its 30-minute half-life allows pulsatile dosing that mirrors natural GH secretion. DAC is preferred by clinicians targeting sustained IGF-1 elevation for body-composition purposes and by patients who cannot commit to nightly injections — the 5.8 to 8.1-day half-life allows twice-weekly dosing. DAC carries the 2006 ConjuChem trial history (Phase 2 halted after one participant death, attributed to unrelated coronary disease). Both versions are research peptides; neither is FDA-approved.
Is tesamorelin better than CJC-1295 because it’s FDA-approved?
For evidence grade, yes — tesamorelin has a Phase 3 RCT with n=412 (Falutz 2007 NEJM PMID 18057338) demonstrating 15.2% visceral fat reduction over 26 weeks. CJC-1295’s human data is limited to the Teichman 2006 pharmacokinetic study and post-2006 community reports. For mechanism, they are pharmacologically the same class (GHRH-receptor agonists). The FDA approval is for HIV-associated lipodystrophy specifically; off-label use in the longevity or body-composition population is inference from the HIV-population data, not direct evidence. Tesamorelin is also 5 to 20 times more expensive than compounded CJC-1295.
When should I inject the stack?
Fifteen to thirty minutes before bed, on an empty stomach (last meal 2 or more hours prior). The rationale: endogenous GH pulses primarily during the first 90 minutes of slow-wave sleep, and aligning the pharmacologic pulse with the natural pulse maximizes the synergy. Injecting after a carb-heavy meal blunts GH release because insulin suppresses GH secretion. Some protocols add a morning dose on training days — no controlled evidence supports the second dose over a single pre-bed dose.
How long can I stay on the stack?
Community pattern is 8 weeks on / 4 weeks off, or 5 nights on / 2 nights off within a week. No controlled trial defines optimal cycle length for research-peptide stacks. Tesamorelin at the FDA-labeled indication (HIV lipodystrophy) is dosed continuously — the label does not specify a cycling requirement — but the off-label body-composition population typically cycles to limit continuous IGF-1 elevation and give the axis recovery windows. Continuous long-term use beyond 6 months warrants quarterly HbA1c and fasting insulin monitoring in addition to IGF-1.
Do I need to monitor labs?
Yes. Baseline IGF-1, fasting glucose, HbA1c, and comprehensive metabolic panel before starting. Recheck IGF-1 at 6 to 8 weeks to confirm the expected rise into the upper quartile of the age/sex reference range without exceeding it. Quarterly on-cycle IGF-1 plus fasting glucose. Off-cycle at 4 weeks to confirm return to baseline. See the IGF-1 Monitoring section above and the Peptide Lab Testing Guide.
Can I stack this with tirzepatide or a GLP-1 for fat loss?
Some patients do, targeting simultaneous appetite suppression (GLP-1) and body-composition improvement (GH stack). This combines two mechanisms of action that are not known to interact pharmacologically, but it also compounds cost, injection burden, side-effect risk, and monitoring requirements. See our Fat Loss Stack Guide for the tirzepatide-plus-BPC-157 approach and consider whether adding a third mechanism is worth the additional complexity. Not recommended for beginners.
What about MK-677 as an oral alternative to ipamorelin?
MK-677 (ibutamoren) is an orally-active ghrelin-receptor agonist — same target class as ipamorelin but different pharmacokinetics. Oral convenience is the appeal; the downside is that MK-677 has a much longer half-life (roughly 24 hours) and produces sustained ghrelin-receptor activation rather than pulsatile stimulation. That sustained activation raises cortisol modestly and produces more edema and hunger than injectable ipamorelin. See our MK-677 Guide for a full comparison.
Is the GH stack safe long-term?
Honestly, we do not know. Tesamorelin has the longest continuous safety experience because of its FDA-approved status in HIV lipodystrophy; the Phase 3 trial extension confirmed durability of effect and no new signals at 52 weeks. CJC-1295 and ipamorelin have thinner long-term human data. The community cycling pattern reflects appropriate caution given the incomplete long-term picture. If you have a personal or family history of cancer, discuss with your physician before starting given the theoretical concern that any pathway raising IGF-1 systemically could accelerate growth of occult malignancies.
What labs should I get before starting?
Baseline: fasting IGF-1, fasting glucose, HbA1c, comprehensive metabolic panel (kidney and liver function), lipid panel, thyroid panel. If considering the aggressive variant, add fasting insulin and optional DEXA scan for baseline body composition. Repeat IGF-1 and fasting glucose at 6-8 weeks and then quarterly. See Peptide Lab Testing Guide for details.
References
All PMIDs below cross-checked against the fresh-session research dossier (RESEARCH-gh-stack-and-libido-pillar.md, 2026-07-11) per rule #530. Two items marked [VERIFY at publish] where the research pass could not complete a direct PubMed abstract fetch and relied on multiple secondary corroborations.
- Teichman SL, Neale A, Lawrence B, Gagnon C, Castaigne JP, Frohman LA. Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults. J Clin Endocrinol Metab. 2006 Mar;91(3):799-805. PMID: 16352683. DOI: 10.1210/jc.2005-1536.
- Raun K, Hansen BS, Johansen NL, Thøgersen H, Madsen K, Ankersen M, Andersen PH. Ipamorelin, the first selective growth hormone secretagogue. Eur J Endocrinol. 1998 Nov;139(5):552-561. PMID: 9849822.
- Beck DE, Sweeney WB, McCarter MD; Ipamorelin 201 Study Group. Prospective, randomized, controlled, proof-of-concept study of the ghrelin mimetic ipamorelin for the management of postoperative ileus in bowel resection patients. Int J Colorectal Dis. 2014 Dec;29(12):1527-1534. PMID: 25331030. DOI: 10.1007/s00384-014-2030-8.
- Falutz J, Allas S, Blot K, Potvin D, Kotler D, Somero M, Berger D, Brown S, Richmond G, Fessel J, Turner R, Grinspoon S. Metabolic effects of a growth hormone-releasing factor in patients with HIV. N Engl J Med. 2007 Dec 6;357(23):2359-2370. PMID: 18057338. [VERIFY at publish — direct PubMed fetch blocked by reCAPTCHA during research pass; corroborated via multiple secondary sources.]
- FDA Egrifta (tesamorelin for injection) prescribing information. Theratechnologies Inc. NDA 022505, approved November 10, 2010. Egrifta SV reformulation approved 2019; Egrifta WR (F8 weekly reconstitution) approved subsequently. Available at accessdata.fda.gov.
- US Department of Health and Human Services. Peptide framework reclassification announcement. February 27, 2026. [VERIFY at publish — HHS document reference.]
- Ho KY, Veldhuis JD, Johnson ML, Furlanetto R, Evans WS, Alberti KG, Thorner MO. Fasting enhances growth hormone secretion and amplifies the complex rhythms of growth hormone secretion in man. J Clin Invest. 1988 Apr;81(4):968-975. PMID: 3127426. [Foundational GH-pulsatility physiology reference.]
- Sikiric P, Sikiric S. FDA framework changes and the return of compounded peptides to Category 1: implications for research-peptide oversight. Editorial context 2026.
- Bowers CY, Momany FA, Reynolds GA, Hong A. On the in vitro and in vivo activity of a new synthetic hexapeptide that acts on the pituitary to specifically release growth hormone. Endocrinology. 1984 May;114(5):1537-1545. PMID: 6714155. [Historical GHRP class discovery reference.]
- Kojima M, Hosoda H, Date Y, Nakazato M, Matsuo H, Kangawa K. Ghrelin is a growth-hormone-releasing acylated peptide from stomach. Nature. 1999 Dec 9;402(6762):656-660. PMID: 10604470. [Ghrelin discovery, mechanistic foundation for GHS-R1a agonist class.]
Last reviewed 2026-07-12 by New Science Labs LLC. This article is educational and does not constitute medical advice.
—






